Sanofi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANOFI, and what generic alternatives to SANOFI drugs are available?
SANOFI has one hundred and twenty-seven approved drugs.
There are eleven US patents protecting SANOFI drugs.
There are two hundred and thirty-seven patent family members on SANOFI drugs in fifty-two countries and one hundred and twenty-two supplementary protection certificates in nineteen countries.
Summary for Sanofi
International Patents: | 237 |
US Patents: | 11 |
Tradenames: | 101 |
Ingredients: | 89 |
NDAs: | 127 |
Patent Litigation for Sanofi: | See patent lawsuits for Sanofi |
PTAB Cases with Sanofi as petitioner: | See PTAB cases with Sanofi as petitioner |
Drugs and US Patents for Sanofi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi | HECTOROL | doxercalciferol | CAPSULE;ORAL | 020862-003 | Jul 13, 2009 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi | HECTOROL | doxercalciferol | INJECTABLE;INJECTION | 021027-002 | Apr 6, 2000 | AP | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | CERUBIDINE | daunorubicin hydrochloride | INJECTABLE;INJECTION | 061876-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-002 | Sep 20, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE | chloroquine phosphate; primaquine phosphate | TABLET;ORAL | 014860-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | SLO-BID | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 088269-001 | Jan 31, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sanofi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | 4,876,248 | ⤷ Try a Trial |
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-005 | Mar 27, 1998 | 4,486,420 | ⤷ Try a Trial |
Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-001 | Jan 31, 2005 | 5,420,319*PED | ⤷ Try a Trial |
Sanofi Aventis Us | PRIMACOR | milrinone lactate | INJECTABLE;INJECTION | 019436-001 | Dec 31, 1987 | 4,313,951*PED | ⤷ Try a Trial |
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-003 | Mar 27, 1998 | 4,692,435 | ⤷ Try a Trial |
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-002 | Jan 30, 1998 | 4,692,435 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
➤ Subscribe | Capsules | 0.5 mcg and 2.5 mcg | ➤ Subscribe | 2009-03-25 |
➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
➤ Subscribe | Capsules | 1 mcg | ➤ Subscribe | 2010-02-12 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2008-12-04 |
➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
➤ Subscribe | Capsules | 0.4 mg | ➤ Subscribe | 2004-12-20 |
➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
➤ Subscribe | Injection | 2 mcg/mL, 2 mL ampules | ➤ Subscribe | 2007-10-15 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
➤ Subscribe | Injection | 2 mcg/mL, 1 mL in 2 mL vial | ➤ Subscribe | 2011-12-28 |
➤ Subscribe | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | ➤ Subscribe | 2009-12-30 |
International Patents for Sanofi Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2015200149 | ⤷ Try a Trial |
Australia | 2016200598 | ⤷ Try a Trial |
Taiwan | I654975 | ⤷ Try a Trial |
China | 106309452 | ⤷ Try a Trial |
Hong Kong | 1206245 | ⤷ Try a Trial |
European Patent Office | 2684564 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sanofi Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0281459 | 9890035-0 98910359 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715 |
0281459 | 98C0036 | France | ⤷ Try a Trial | PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001 |
1667986 | 141 5019-2013 | Slovakia | ⤷ Try a Trial | FIRST REGISTRATION NO/DATE: EU/1/11/676/001 20110317 |
3300601 | C202230030 | Spain | ⤷ Try a Trial | PRODUCT NAME: COMBINACION DE DAUNORUBICINA Y CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823 |
1110543 | SPC/GB08/005 | United Kingdom | ⤷ Try a Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
1744764 | 18C1047 | France | ⤷ Try a Trial | PRODUCT NAME: DAUNORUBICINE + CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.